Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SeaStar Medical Holding (ICU) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for SeaStar Medical Holding (ICU) over the last 3 years, with Q3 2025 value amounting to $11.3 million.

  • SeaStar Medical Holding's Cash from Financing Activities rose 9144.79% to $11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.9 million, marking a year-over-year increase of 4532.23%. This contributed to the annual value of $17.6 million for FY2024, which is 6948.34% up from last year.
  • According to the latest figures from Q3 2025, SeaStar Medical Holding's Cash from Financing Activities is $11.3 million, which was up 9144.79% from $4.0 million recorded in Q2 2025.
  • In the past 5 years, SeaStar Medical Holding's Cash from Financing Activities registered a high of $11.3 million during Q3 2025, and its lowest value of -$1.0 million during Q2 2024.
  • Over the past 3 years, SeaStar Medical Holding's median Cash from Financing Activities value was $4.4 million (recorded in 2024), while the average stood at $4.5 million.
  • As far as peak fluctuations go, SeaStar Medical Holding's Cash from Financing Activities tumbled by 16973.23% in 2024, and later surged by 49498.03% in 2025.
  • Quarter analysis of 3 years shows SeaStar Medical Holding's Cash from Financing Activities stood at $4.6 million in 2023, then fell by 3.44% to $4.4 million in 2024, then soared by 155.19% to $11.3 million in 2025.
  • Its Cash from Financing Activities stands at $11.3 million for Q3 2025, versus $4.0 million for Q2 2025 and $6.1 million for Q1 2025.